USFDA’s inspection of Divis Lab: zero observations

USFDA's inspection of Divis Lab: zero observations

Picture: Pixabay

Divis’s Laboratories has received zero Form 483 observations from US Food and Drug Administration (FDA) for Andhra Pradesh facility.

The company’s unit-II at village Chippada, Bheemunipatnam District, Andhra Pradesh has had an inspection by the US Food and Drug Administration (FDA) from January 27, 2020, to January 31, 2020., the company said in a BSE filing.

Also read: USFDA’s inspection of Biocon with 5 observations

Divi’s Laboratories is the leading manufacturer of APIs (Active pharmaceuticals ingredients), Intermediates and registered starting materials offering high quality products with the highest level of compliance and integrity to over 95 countries.

Divi’s Lab has been established for more than 29 years in Hyderabad, India with two manufacturing units and is among the top pharmaceuticals companies in India.


Please enter your comment!
Please enter your name here